Abstract
BackgroundSpecific biomarkers for outcome prediction of lung squamous cell carcinoma (LUSC) are still lacking. This study assessed the prognostic value of differentially expressed miRNAs of LUSC patients.ResultsTwelve of the 133 most significantly altered miRNAs were associated with overall survival (OS) across different clinical subclasses of the Cancer Genome Atlas (TCGA) LUSC cohort. A linear prognostic model of seven miRNAs was developed to divide patients into high- and low-risk groups. Patients assigned to the high-risk group exhibited poor OS compared with patients in the low-risk group, which was further validated in the validation cohort and entire LUSC cohort.MethodsMiRNA expression profiles with clinical information of 447 LUSC patients were obtained from TCGA. Most significantly altered miRNAs were identified between tumor and normal samples. Using survival analysis and supervised principal components method, a seven-miRNA signature for prediction of OS of LUSC patients was established. Survival receiver operating characteristic (ROC) analysis was used to assess the performance of survival prediction. The biological relevance of predicted miRNA targets was also analyzed using bioinformatics method.ConclusionsThe current study suggests that seven-miRNA signature may have clinical implications in the outcome prediction of LUSC.
Highlights
Lung cancer is the most common and fatal cancer in the world [1]
The current study suggests that seven-miRNA signature may have clinical implications in the outcome prediction of lung squamous cell carcinoma (LUSC)
The patients were separated into the training set (n=224) and testing set (n=223) randomly
Summary
Lung cancer is the most common and fatal cancer in the world [1]. Non-small cell lung cancer (NSCLC) is the most frequent type of lung cancer and can be further subtyped mainly as adenocarcinomas (LAD) and squamous cell carcinomas (LUSC). Effective biomarkers to identify patients with high recurrence and death risk are still lacking. Since the genetic and epigenetic alterations between LUSC and lung LAD are quite different, the targeted agents for LAD cannot be applied to LUSC. There is an urgent need to identify effective biomarkers for the prognosis of LUSC. Specific biomarkers for outcome prediction of lung squamous cell carcinoma (LUSC) are still lacking. This study assessed the prognostic value of differentially expressed miRNAs of LUSC patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
